Atossa Therapeutics (ATOS) Interest Expenses (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Interest Expenses of $214000.0 for Q4 2025, up 45.58% year-over-year from $147000.0 in Q4 2024, and down 52.01% quarter-over-quarter from $445924.0 in Q3 2025.
Atossa Therapeutics (ATOS) Interest Expenses (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Interest Expenses for 15 consecutive years, with $214000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 45.58% year-over-year to $214000.0; the TTM figure through Dec 2025 stood at $599000.0 (up 53.2% YoY), while the FY2025 annual figure was $400000.0, down 98.64% from the prior year.
- Interest Expenses slipped to $214000.0 in Q4 2025 per ATOS's latest filing, from $445924.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $8.4 million in Q1 2024 and bottomed at -$39000.0 in Q4 2021.
- Historically, Interest Expenses has averaged $928837.4 across 5 years, with a median of $65500.0 in 2023.
- Annual changes were most pronounced in 2021 — Interest Expenses plunged 407.09% — and 2024, when it soared 19545.81%.
- Atossa Therapeutics' Interest Expenses stood at -$39000.0 in 2021, then jumped by 351.28% to $98000.0 in 2022, then surged by 66.33% to $163000.0 in 2023, then decreased by 9.82% to $147000.0 in 2024, then surged by 45.58% to $214000.0 in 2025.
- Business Quant data shows ATOS's Interest Expenses at $214000.0 in Q4 2025, $445924.0 in Q3 2025, and $343096.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50,000.00 |
| Jun 30, 2026 | 50,000.00 |
| Mar 31, 2026 | 53,000.00 |
| Mar 31, 2026 | 53,000.00 |
| Dec 31, 2025 | 214,000.00 |
| Dec 31, 2025 | 214,000.00 |
| Sep 30, 2025 | 445,924.00 |
| Sep 30, 2025 | 445,924.00 |
| Jun 30, 2025 | 343,096.00 |
| Jun 30, 2025 | 343,096.00 |
| Mar 31, 2025 | 75,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Sep 30, 2024 | 6.09 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 8.35 Mn |
| Mar 31, 2024 | 8.35 Mn |